Literature DB >> 30606419

Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.

K Dahan1, C Johannet2, E Esteve3, E Plaisier4, H Debiec5, P Ronco4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30606419     DOI： 10.1016/j.kint.2018.08.045

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  12 in total

1.  Management of Membranous Nephropathy after MENTOR.

Authors:  Claire Trivin-Avillach; Laurence H Beck
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-18       Impact factor: 8.237

2.  High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Authors:  Barbara Seitz-Polski; Karine Dahan; Hanna Debiec; Alexandra Rousseau; Marine Andreani; Christelle Zaghrini; Michel Ticchioni; Alessandra Rosenthal; Sylvia Benzaken; Ghislaine Bernard; Gérard Lambeau; Pierre Ronco; Vincent L M Esnault
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-24       Impact factor: 8.237

3.  Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY.

Authors:  Nattawat Klomjit; Ladan Zand
Journal:  Kidney360       Date:  2021-04-19

4.  Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO.

Authors:  Nestor Oliva-Damaso; Andrew S Bomback
Journal:  Kidney360       Date:  2021-04-19

Review 5.  Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.

Authors:  Maxime Teisseyre; Marion Cremoni; Sonia Boyer-Suavet; Caroline Ruetsch; Daisy Graça; Vincent L M Esnault; Vesna Brglez; Barbara Seitz-Polski
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 6.  Advances in Membranous Nephropathy.

Authors:  Pierre Ronco; Emmanuelle Plaisier; Hanna Debiec
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

Review 7.  Rituximab in Membranous Nephropathy.

Authors:  Philipp Gauckler; Jae Il Shin; Federico Alberici; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Martijn W F van den Hoogen; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Gert Mayer; Rutger Maas; Masahiro Muto; Sergey Moiseev; Balazs Odler; Ruth J Pepper; Luis F Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D Salama; Ulf Schönermarck; Mårten Segelmark; Lee Smith; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler
Journal:  Kidney Int Rep       Date:  2021-01-13

8.  Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy.

Authors:  Maxime Teisseyre; Sonia Boyer-Suavet; Marion Crémoni; Vesna Brglez; Vincent Esnault; Barbara Seitz-Polski
Journal:  Kidney Int Rep       Date:  2021-01-29

9.  Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.

Authors:  Nicolas Hanset; Emmanuel Esteve; Emmanuelle Plaisier; Catherine Johanet; Pierre-Antoine Michel; Jean-Jacques Boffa; Patrick Fievet; Laurent Mesnard; Johann Morelle; Pierre Ronco; Karine Dahan
Journal:  Kidney Int Rep       Date:  2019-12-20

Review 10.  Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?

Authors:  Lucia Del Vecchio; Marco Allinovi; Paolo Rocco; Bruno Brando
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.